Key result
Anti-CD19 CAR-T cell therapy is linked to increased 30-day vascular inflammation in treatment responders.
Cohort (n=50)
No
Answers are grounded in this paper and cite their sources.
Retrospective study reveals increased vascular inflammation in lymphoma patients responding to anti-CD19 CAR-T therapy, highlighting the need for cardiovascular surveillance.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Camilli et al. (2025) conducted a cohort in Relapsed or refractory CD19+ B-cell aggressive lymphomas (n=50). Anti-CD19 CAR-T cell therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, or Brexucabtagene Autoleucel) vs. Non-responders to CAR-T therapy and matched autologous haematopoietic stem cell transplantation (HSCT) controls was evaluated on Change in arterial and venous wall inflammation (SUVmax on 18F-FDG PET/CT) from baseline to 30 days by treatment response (time-response interaction) (beta -0.15, 95% CI -0.27 to -0.03, p=0.015). Anti-CD19 CAR-T cell therapy increased 30-day vascular inflammation (SUVmax) in treatment responders compared with non-responders.
Synapse has enriched 10 related papers. Consider them for comparative context: